Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.56 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.55 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27376752 | 1.00 | CRBN (0.56) | CRBNDDB1GSPT1PDK2 | |
| SCHEMBL20046720 | 1.00 | CRBN (0.56) | CRBNDDB1GSPT1PDK2 | |
| SCHEMBL31727437 | 0.93 | CRBN (0.52) | CRBNDDB1GSPT1 | |
| SCHEMBL30720169 | 0.93 | CRBN (0.56) | CRBNDDB1 | |
| SCHEMBL29547522 | 0.93 | CRBN (0.56) | CRBNDDB1 | |
| SCHEMBL27301548 | 0.93 | CRBN (0.56) | CRBNDDB1 | |
| SCHEMBL20046704 | 0.93 | CRBN (0.56) | CRBNDDB1 | |
| SCHEMBL30720192 | 0.93 | CRBN (0.56) | CRBNDDB1 | |
| SCHEMBL31611548 | 0.93 | CRBN (0.56) | CRBNDDB1 | |
| SCHEMBL31134759 | 0.91 | CRBN (0.50) | CRBNDDB1GSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709486-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Celgene Corporation (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4638454-A1 | SUBSTITUTED IMIDAZO-BASED COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK3 | Celgene Corporation (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4598905-A2 | CEREBLON-RECRUITING BCL-XL/BCL-2 DUAL DEGRADERS | University of Florida Research Foundation, Incorporated (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4587127-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics Incorporated (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4558495-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Bristol-Myers Squibb Company (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024233748-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | CELGENE CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024137743-A1 | SUBSTITUTED IMIDAZO-BASED COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK3 | CELGENE CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024077023-A2 | CEREBLON-RECRUITING BCL-XL/BCL-2 DUAL DEGRADERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024059806-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024020084-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-4240743-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics, Incorporated (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2022099117-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-05-12 | — | — | WO | disclosed |